Wednesday, June 19, 2019

Facts About Sickle cell Disease

  • Beginning in the teen years and into adulthood, the health of patients with SCD often gets worse. This period is called “transition.” Young adults with SCD suffer from more frequent SCD-related complications than younger pediatric patients.
  • During transition, people with SCD often face many barriers to care:
    • The number of physicians trained and willing to treat patients with SCD, especially adults is limited.
    • Young adults with SCD often do not receive HU because few adult healthcare providers are knowledgeable about SCD.
    • Healthcare providers may inaccurately perceive SCD patients as drug-seekers and may doubt their severity of pain. As a result, patients with SCD often experience longer wait times to see a doctor and to get pain medication when visiting the emergency department. 

Sunday, June 16, 2019

Restless Legs Syndrome Tied to Gut Health

SAN ANTONIO — Preliminary research suggests an association between small intestine bacterial overgrowth (SIBO) and restless legs syndrome (RLS), supporting emerging research linking gut microbial health to sleep health.
While the study is ongoing and recruitment just beginning, the researchers found SIBO in all 7 RLS patients studied to date.
"We found very high rates of small intestinal bacterial overgrowth in these RLS patients," lead investigator Daniel J. Blum, PhD, adjunct clinical instructor at Stanford Center for Sleep Sciences and Medicine in Redwood City, California, told Medscape Medical News. Exploring this relationship further could lead to new ways to detect, prevent, and treat RLS, he said.
The study was presented here at SLEEP 2019: 33rd Annual Meeting of the Associated Professional Sleep Societies.

RLS Poorly Understood

Although the cause of RLS is not fully understood, a relative state of brain iron deficiency has been described in patients with RLS and appears to induce changes in several pathways known to be involved in the disease, said Blum.
Insufficient iron may be secondary to dietary iron deficiency or, potentially, gut inflammation. Blum and colleagues hypothesized that SIBO, a condition associated with gut dysbiosis, may be associated with RLS.
Participants for the study were recruited at the Stanford Sleep Center for 3 groups: RLS and low peripheral iron stores (<50 and="" control="" group="" insomnia="" iron="" ml="" ng="" normal="" or="" p="" peripheral="" rls="" saturation="" stores="" transferrin="">As part of the study, they completed questionnaires concerning sleep and SIBO symptoms and took home a fecal collection kit and a SIBO breath test kit. Fecal samples were examined by the University of Minnesota Genomics Center, and SIBO breath samples were evaluated by Aerodiagnostics, a Massachusetts-based medical laboratory, for hydrogen and methane abnormalities.
The 7 participants diagnosed with RLS who have completed the protocol to date include 3 men and 4 women. All had poor sleep quality based on the Pittsburgh Sleep Quality Index and moderate to severe symptoms based on the International Restless Legs Scale.
SIBO was present in all 7 participants (100%). In contrast, SIBO rates in the general population are estimated to be between 6% and 15%, suggesting SIBO may be much more common in the RLS population, Blum reported.
"There is an unpublished study showing that [for] people who have this overlap of SIBO and RLS, if you treat the SIBO, the RLS significantly improves," Blum said.

New Insight

Commenting on the study, American Academy of Sleep Medicine spokesperson Nitun Verma, MD, noted that the study is "small but very interesting."
"Restless legs is a relatively common disorder and we have really not gotten to the bottom of why people have it. Patients want to know why they have restless legs and it's terrible that we can't give them a good answer. This study opens the door to deeper research on potential causation," said Verma, who was not involved with the current study.
Dianne Augelli, MD, sleep medicine expert at Weill Cornell Medicine and NewYork-Presbyterian Hospital in New York City, also believes the SIBO-RLS link is "interesting" but cautioned that "much larger studies are needed" to replicate the results. She was not associated with the current research.
In addition, it can be "complicated" to treat SIBO, Augelli told Medscape Medical News, "and that treatment may lead down a pathway that can cause harm. Do we treat with antibiotics and end up making something else worse?"
The study was funded by a Pau Innovation Gift Fund Seed Grant. Blum, Verma, and Augelli have disclosed no relevant financial relationships.
SLEEP 2019: 33rd Annual Meeting of the Associated Professional Sleep Societies: Abstract 0009. Presented June 9, 2019.

Saturday, June 15, 2019

Seven Key Health Measures Can Help Predict Future Heart Disease Risk

Heart disease holds a firm grip on both men and women, regardless of age, due to the lifestyle changes such as smoking and drinking alcohol, spiking stress, air pollution and increasing consumption of salt, sugar, and fat.







Heart disease holds a firm grip on both men and women, regardless of age, due to the lifestyle changes such as smoking and drinking alcohol, spiking stress, air pollution and increasing consumption of salt, sugar, and fat.


Seven key measures of heart health may help predict future risk of cardiovascular disease, according to researchers. They added that improving these measures may also help decrease the risk of CVD in the future.

The team of researchers, including three from Penn State, studied how seven key health measures -- like diet, exercise and blood pressure -- were related to people's cardiovascular health over time.

They identified five patterns of how well people did or did not do on the seven health measures over time. These patterns were able to help predict participants' future risk of CVD.

For example, people who consistently scored well in the seven metrics had a lower chance of CVD than people who did not. The researchers also found that improving these metrics over time was related to a lower risk of CVD in the future.

Xiang Gao, associate professor of nutritional sciences and director of the Nutritional Epidemiology Lab at Penn State, said the study -- published in JAMA Network Open -- suggests that people can help influence their risk of CVD in the future.

"In our study population, and probably across the world, there are many people who have suboptimal or poor heart health," Gao said. "But, even though most people don't meet the ideal criteria for all seven metrics, if we can work to improve those measures, the future risk of CVD can still decrease."

The American Heart Association identified the seven health metrics as the most important predictors of heart health. They include four behaviors that people have control over and three biometrics that should be kept at healthy levels.

The modifiable behaviors include not smoking, maintaining a healthy weight, eating healthy, and staying physically active. The bio-metrics are blood pressure, cholesterol and blood sugar.

Each metric has a poor, intermediate, or ideal score. For example, smoking regularly would be considered 'poor,' smoking within the past 12 months would be 'intermediate,' and never smoking or quitting more than a year ago would be 'ideal.' Combining the score for all seven metrics -- 0 for poor, 1 for intermediate and 2 for ideal -- results in an overall 'cardiovascular health score,' or CHS.

"Only about 2 percent of people in the United States and other countries meet all the ideal requirements for these seven factors," Gao said. "This raises the question of whether improving these metrics is related to lower future risk of CVD. It should, but no one had the data to support this idea."

A team of researchers used data from 74,701 Chinese adults from the Kailuan Study. At the beginning of the study, the participants completed questionnaires about their health and underwent clinical exams and lab tests three times in the first four years. Across the following five years, the researchers kept track of any new onset CVD cases in the participants.

After the information was gathered, the researchers analyzed the data to see how CHS during the first four years was associated with whether or not the participants developed CVD subsequently. They found five distinct patterns -- or trajectories -- that people followed throughout the four years.

These trajectories included maintaining high, medium, or low CHS, as well as increasing and decreasing CHS over time. Gao said these different trajectories were associated with different risks for developing CVD in the future.

"For example, about 19 percent of participants were able to maintain a better cardiovascular health score over the four years," Gao said. "We found that those people had a 79 percent lower chance of developing heart disease in the future than people who maintained a low cardiovascular health score."

Gao said they found similar results when they analyzed risk for stroke and myocardial infarction -- commonly referred to as a heart attack.

"We also examined whether improving cardiovascular health score over time affected the future risk of CVD," Gao said. "We found that improvement of overall cardiovascular health over time-related to lower future CVD in this population, even for those with poor cardiovascular health status at the beginning of the study."

Additionally, the researchers were curious about whether one health measure was more important than the others. They ran repeated tests, removing a different, single health measure each time. They found that the scores still predicted future CVD risk in similar ways.

"This suggests that overall cardiovascular health is still the most important thing and that one factor isn't more important than the others," Gao said. "It also helps confirm that these seven metrics are valid and a very useful tool for developing a strategy for cardiovascular disease prevention."

Source: Eurekalert

Friday, June 7, 2019

National Education Policy 2019: Pluralistic healthcare education

The government has released a draft National Education Policy 2019, which proposes to make changes in education including healthcare education.
The policy is in the public domain, with comments sought from all stakeholders till June 30.
A key recommendation of the new education policy as far as medical education is concerned is pluralistic healthcare education and delivery.
P16.8.2: Pluralistic healthcare education and delivery: The first year or two of the MBBS course will be designed as a common period for all science graduates after which they can take up MBBS, BDS, Nursing or other specialisations. Common foundational courses based on medical pluralism will be followed by core courses focused on specific systems, and electives that encourage bridging across systems. Graduates from other medical disciplines such as nursing, dental etc., will also be allowed lateral entry into the MBBS course.  A medical education qualification framework to achieve this will be developed in conjunction with the NMC...”
This means that after class 12, students aspiring to become healthcare professionals will first take up a common 2 year (or 1 year) course of basic sciences after clearing a common entrance test and then they can choose a system of medicine be it MBBS, dentistry, nursing, Ayush, occupational health, physiotherapy, etc.
What is not clear is how students would be selected for their specific system of choice. Would it be through an entrance exam? Would each system hold its own separate exam or a common exam? Or there will be only one exam at this level and for basic course there will be no common exam.
 The initial two-year course may enable a student to take up teaching as a vocation.
Also, the terms “bridging” and “lateral entry” have been used out of context here and have created ambiguity and are therefore open to misinterpretation.
There are debatable issues, which need to be discussed in stakeholders meeting and several challenges in their implementation should be anticipated and addressed.

Fainting During Pregnancy Can Be a Sign of Problems for Both Mother and Baby

Women have long been told fainting is a common but harmless symptom of pregnancy, but new research published in the Journal of the American Heart Association found that it may indicate issues for both the baby and mother’s health, especially when it occurs during the first trimester.

For the study, Safia Chatur, MD, University of Calgary, Calgary, Alberta, and colleagues reviewed birth records of 481,930 babies born between 2005 and 2014, as well as medical records of the mothers for 1 year after delivery, looking for frequency, timing, and outcomes of fainting episodes.

The researchers found that roughly 1% of expectant mothers fainted. Overall, 32.3% of the syncope episodes first occurred in the first trimester, 44.1% in the second trimester, and 23.6% in the third trimester; and 8% of pregnancies had >1 episode of syncope.

Compared with women without syncope, women who experienced syncope were younger and primiparous.

The rate of preterm birth was higher in pregnancies with syncope during the first trimester (18.3%) compared with the second (15.8%) and third trimesters (14.2%) and pregnancies without syncope (15%; P< .01).

The incidence of congenital anomalies among children born of pregnancies with multiple syncope episodes was significantly higher (4.9%) compared with children of pregnancies without syncope (2.9%; P< .01).

Within 1 year after delivery, women with syncope during pregnancy had higher rates of cardiac arrhythmias and syncope episodes than women with no syncope during pregnancy.

Women who faint during pregnancy should report it to their physicians, who should monitor the women and their babies more closely, said Padma Kaul, PhD, University of Calgary.

“Pregnancy is a natural stress test for the woman’s system,” she said. “Fainting during pregnancy may identify women who are at higher risk of cardiovascular complications down the road.”

Until now, research about fainting during pregnancy relied on anecdotal reporting and a small number of case studies. The pattern of issues for mothers and babies was only revealed when researchers were able to review a large number of birth records from a 10-year time period.

While a large proportion of the population faints at some point in their lifetime, the underlying causes can be difficult to diagnose and can range from life-threatening to benign.

While the study shows a correlation between fainting and health issues for mothers and babies, it cannot pinpoint causes or pre-existing conditions that might be responsible, said Dr. Kaul.

“It is a chicken-and-egg problem, so the associations need to be worked out through further study,” she concluded.

Monday, June 3, 2019

Aspirin to prevent preeclampsia: When to start and how much to give?

Empirical use of aspirin to prevent myocardial infarction dates back to 1950. It would take another 20 years for Sir John Vane to describe aspirin’s primary mechanism of action, inhibition of cyclooxygenase, for which he shared a Nobel Prize. In 1975 aspirin’s inhibitory effect on platelet-induced arterial thrombosis was described by Weiss and associates. Later studies showed that this antithrombotic property was mediated by inhibition of the synthesis of platelet thromboxane A2 (TXA2), a potent platelet aggregator and vasoconstrictor.
Drawing on these anti-platelet effects, in 1978 Dr Bob Goodlin and colleagues were the first to report the use of aspirin to prevent preeclampsia.They treated a thrombocytopenic patient with a history of recurrent early–onset severe preeclampsia using high doses of aspirin starting at 15 weeks, and reported that she delivered a live-born, although growth-restricted, infant at 34 weeks gestation. Eleven years later, Schiff and colleagues conducted the first randomized, placebo-controlled clinical trial of low-dose aspirin for the prevention of preeclampsia in high-risk women.

The American College of Obstetricians and Gynecologists recommends initiating use of low-dose aspirin (60 to 80 mg/d) during the late first trimester to prevent preeclampsia in women with a medical history of early-onset preeclampsia and preterm delivery (preeclampsia in more than 1 previous pregnancy1.
The World Health Organization recommends the use of low-dose aspirin (75 mg/d) starting as early as 12 to 20 weeks of gestation for high-risk women (i.e., those with a history of preeclampsia, diabetes, chronic hypertension, renal or autoimmune disease, or multifetal pregnancies). It states that there is limited evidence regarding the benefits of low-dose aspirin in other subgroups of high-risk women2.
The National Institute for Health and Clinical Excellence recommends that women at high risk for preeclampsia (i.e., women with a history of hypertension in a previous pregnancy, chronic kidney disease, autoimmune disease, type 1 or 2 diabetes, or chronic hypertension) take 75 mg/d of aspirin from 12 weeks until delivery. It recommends the same for women with more than 1 moderate-risk factor (first pregnancy, age ≥40 years, pregnancy interval >10 years, body mass index ≥35 kg/m2, family history of preeclampsia, or multifetal pregnancies)3.
The American Heart Association and the American Stroke Association recommend that women with chronic primary or secondary hypertension or previous pregnancy-related hypertension take low-dose aspirin from 12 weeks until delivery4.
The American Academy of Family Physicians recommends low-dose aspirin (81 mg/d) after 12 weeks of gestation in women who are at high risk for preeclampsia5

About Me